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Sarah-Jane Schramm1, Anna E. Campain2, Richard A. Scolyer3,4,5, Yee Hwa Yang2 and Graham J. Mann1,3
In melanoma, there is an urgent need to identify novel
biomarkers with prognostic performance superior to
traditional clinical and histological parameters. Gene
expression-based prognostic signatures offer pro-
mise, but studies have been challenged by sample
scarcity, cohort heterogeneity, and doubts about the
efficacy of such signatures relative to current clinical
practices. Motivated by new studies that have begun
to address these challenges, we reviewed prognostic
signatures derived from gene expression micro-
array analysis of human melanoma tissue. We used
REMARK-based criteria to select the most relevant
studies and directly compared their signature gene
lists. Through functional ontology enrichment analy-
sis, we observed that these independent data sets
converge in part upon immune response processes
and the G-protein signaling NRAS-regulation pathway,
both important in melanoma development and pro-
gression. The signatures correctly predicted patient
outcome in independent gene expression data sets
with some notably low misclassification rates, parti-
cularly among studies involving more advanced-stage
tumors. This successful cross-validation indicates that
gene expression analysis-based signatures are becom-
ing translationally relevant to care of melanoma
patients, as well as improving understanding of the
aspects of melanoma biology that determine patient
outcome.
Journal of Investigative Dermatology (2012) 132, 274–283; doi:10.1038/
jid.2011.305; published online 29 September 2011
INTRODUCTION
In the past decade, gene expression microarray (GEMA)
technology has shown fluctuating promise of enhancing or
even replacing current prognostic strategies in the manage-
ment of cancer (Hoek, 2007; Shendure, 2008). The prospect
of predicting clinical tumor behavior on the basis of its
transcriptome remains enticing, but has not yet been realized
for most types of cancer (Subramanian and Simon, 2010;
Varmus, 2010) including melanoma, because discriminating
gene signatures remain elusive. Perhaps, the most advanced
use of prognostic GEMAs in a clinical setting is in the case
of breast cancer patients. Currently, the US Food and
Drug Administration (FDA)-approved MammaPrint 70-gene
signature (van’t Veer et al., 2002) is undergoing evaluation
in a prospective, randomized clinical trial comparing it
with traditional clinicopathological criteria for selecting
patients for adjuvant chemotherapy (MINDACT Trial: http://
www.eortc.be/services/unit/mindact/MINDACT_websiteii.asp).
In addition, for estrogen receptor-positive, lymph node-
negative breast cancers, the GEMA-derived Oncotype Dx
reverse transcriptase-PCR assay (Genomic Health, Redwood
City, CA; Paik et al., 2004) is being used to identify patients
with high risk of distant recurrence who may benefit from
chemotherapy. Skepticism remains, however, that these
signatures and others similar to them (e.g., Theros, MapQuant
Dx) will enhance clinical decision making and justify their
costs (which in some instances are more than US$ 5,000).
Questions center primarily around the capacity of GEMAs to
outperform current factors in prognostication and, more
recently, their potential redundancy in the wake of massively
parallel sequencing technologies. Nevertheless, there is
evidence that their prognostic power in clinical practice
would at least complement traditional factors (Weigelt et al.,
2010).
For melanoma, there has hitherto been no such clinical
application of GEMAs (Figure 1). This situation is a special
problem because disseminated melanoma is one of the most
aggressive cancers (Thompson et al., 2009) and, despite the
recent advances of BRAF target therapies (Flaherty et al.,
2010; Kefford et al., 2010), surgical resection remains the
mainstay of treatment. Prognosis is currently assigned almost
entirely on the basis of a limited set of clinical and
histopathological features (Balch et al., 2009). For patients
with clinically localized primary cutaneous melanoma,
their prognosis is primarily influenced by tumor thickness,
ulcerative state, and dermal mitotic rate. For melanoma
patients with metastatic disease, prognosis is influenced by
the number, site, and size of metastases, as well as by clinical
REVIEW
274 Journal of Investigative Dermatology (2012), Volume 132 & 2012 The Society for Investigative Dermatology
Received 14 April 2011; revised 18 July 2011; accepted 1 August 2011;
published online 29 September 2011
1Sydney Medical School, The University of Sydney at Westmead Millennium
Institute, Sydney, New South Wales, Australia; 2School of Mathematics and
Statistics, The University of Sydney, Sydney, New South Wales, Australia;
3Melanoma Institute Australia, Sydney, New South Wales, Australia; 4Tissue
Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney,
New South Wales, Australia and 5Discipline of Pathology, Sydney Medical
School, The University of Sydney, Sydney, New South Wales, Australia
Correspondence: Sarah-Jane Schramm, Melanoma Genomics and Genetic
Epidemiology Research Group, The University of Sydney at Westmead
Millennium Institute, PO Box 412, Westmead, New South Wales 2145,
Australia. E-mail: graham.mann@sydney.edu.au
Abbreviations: AJCC, American Joint Committee on Cancer; GEMA, gene
expression microarray analysis; TNM, tumor, node, metastasis
information such as serum lactate dehydrogenase level
among other parameters. Although this approach is useful
for assigning broad probabilities of relapse, it has limited
predictive power at the level of individual patients and has no
direct implications for personalizing therapy. Therefore, the
search for novel molecular biomarkers has been intense
(reviewed in Gould Rothberg et al., 2009a, b; Schramm and
Mann, 2011). For ideal clinical relevance, GEMA-derived
molecular subgroups should be readily and reproducibly
identifiable, should show clear and independent relationships
with specific survival outcomes (prognostic signatures) or
therapy options (predictive signatures), and should do so with
added or greater sensitivity than the current set of biomarkers.
In the most recent review of melanoma prognostic
signatures, Timar et al. (2010) compared signature gene lists
derived from GEMA assays of human melanoma tissue
2000
Molecular classification of cutaneous malignant melanoma by gene expression profiling. Bittner et al., Nature
Gene expression profiling of primary cutaneous melanoma predicts clinical outcome. Winnepenninckx et al.,
JNCI
Gene expression profiling in stage III melanoma predicts clinical outcome. John et al., CCR
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting
patient survival. Bogunovic et al., PNAS
Gene expression profiling of paraffin-embedded primary melanoma identifies increased osteopontin
expression as predictive of reduced relapse-free survival. Conway et al., CCR
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Figure 1. Timeline of selected key events in the evolution of prognostic/predictive signatures in melanoma (in black text) compared with breast cancer
(in gray text). *MINDACT (Microarray In Node-negative and 1–3 positive lymph node Disease may Avoid ChemoTherapy) study, a prospective randomized
study comparing the MammaPrint 70-gene signature with common clinical–pathological criteria in selecting patients for adjuvant chemotherapy in breast
cancer with 0–3 positive nodes. ^Oncotype DX, a 21-gene quantitative RT-PCR (qRT-PCR) assay for formalin-fixed, paraffin-embedded, estrogen receptor
(ER)-positive, lymph node–negative breast cancers to predict risk of recurrence.
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(Bittner et al., 2000; Mandruzzato et al., 2006; Winnepen-
ninckx et al., 2006; John et al., 2008). They found that there
was little overlap between the signatures, both within and
between the four studies that they compared, and attributed
this mostly to sample heterogeneity. In the months since that
review, melanoma research has experienced a surge in
progress, with three special developments underpinning the
timeliness of the current review. First, minimum standards for
the general methodological approach of GEMA-based prog-
nostic/predictive biomarker discovery (e.g., sample selection
and multivariate statistical analysis as discussed in Allison
et al., 2006; Subramanian and Simon, 2010; Schramm and
Mann, 2011) have been promulgated to enhance their
translational reliability. Second, there has been a number of
rigorous, independent publications describing outcome-
related class prediction in human melanoma samples (see,
e.g., Jo¨nsson et al., 2010; Mann et al., 2010; Figure 1).
Finally, the encouraging progress of anti-BRAF agents in
managing advanced-stage melanoma patients has reinforced
the pressing need to dissect melanomas into distinct
subpopulations for the purpose of personalized therapy
(Arkenau et al., 2010). Taken together, these advances
warrant an updated review of GEMA-based prognostic/
predictive signatures in melanoma.
In this review, we examine the key studies involving
GEMA-based work conducted using human melanoma
samples in a prognostic/predictive study-design context. To
capture all such studies, we first conducted a comprehensive
survey of the literature (see Schramm and Mann, 2011 for
search parameters). Inclusion in this review required
researchers to have a clear hypothesis for supervised
classification, and a function or rule used to classify patients
where the predicted class was a prognosis-related outcome
such as survival or disease-free progression. We excluded
studies in which signatures were not validated using
independent data sets and/or in which the signature was
not assessed for its performance compared with current
prognostic factors (multivariate testing). We compared the
signatures among eligible studies (Table 1) using two separate
methods: we first used MetaCore (from GeneGo, St Joseph,
MI) to directly compare the prognostic signature gene lists
with each other to identify areas of potential convergence
between them that may drive new hypotheses about
recurring, aberrant pathways in melanoma. Second, we
conducted a formal and systematic cross-validation study in
which the capacity of each signature to predict outcome in
each of the other selected expression data sets was examined.
We observed that carefully selected, independent studies are
extracting some similar biological information about gene
expression differences between patients with good and poor
survival outcomes, although from different biomarkers.
Specifically, the consistent observation of altered immune
response regulation across GEMA studies suggests that
immune-related molecules are strong candidates as poten-
tially valuable biomarkers. Interstudy agreement such as this
is broadly useful in highlighting potential directions for future
research and can add valuable knowledge to understanding
basic melanoma biology per se. We also believe that recent
studies support prospects for the potential integration of the
best of traditional and gene expression-based approaches in
clinical practice. Finally, we provide commentary on future
directions in the area as work in the field moves forward in
the wake of the breast cancer precedent and amid the
transforming landscape of genomic medicine.
PROGNOSTIC SIGNATURES IN MELANOMA
2006: 254-gene (element) expression signature
The earliest eligible study, referred to here as the Winne-
penninckx study (Winnepenninckx et al., 2006), involved
analysis of 58 primary cutaneous melanoma samples and
identified a 254-gene (element) expression signature asso-
ciated with a 4-year distant metastasis-free survival. The
performance of the classifier was tested in an independent
sample set of primary cutaneous melanomas in which 11 out
of 17 cases were correctly categorized with respect to their
known survival outcome. The potential clinical use of the
classifier was then compared with the predictive accuracy of
traditional primary tumor-staging factors, tumor thickness,
and the presence of ulceration. The researchers first
generated a clinical prediction rule whereby patients with
nonulcerated primary melanoma 44mm thick, or patients
with an ulcerated melanoma42mm thick, were classified as
having poor prognosis, whereas all other patients were
classified as having favorable prognosis. Considering these
two factors, 28% of patients were misclassified, whereas the
254-gene (element) signature misclassified 29% of the cases
in which the probability of randomly achieving that
misclassification rate was 0.04. Bioinformatics analyses
highlighted DNA replication and repair-related genes as
being overrepresented within the data set (Kannengiesser
et al., 2008; Kauffmann et al., 2008). Although this work
initiated the discovery of prognostic signatures in melanoma
and led to new insights into biological processes, it has not
directly progressed into a clinical application, nor has it led to
a change in clinical practice.
2008: 21-gene (element) expression signature
In the next eligible study to emerge (John et al., 2008),
researchers used oligonucleotide arrays (30,888 probes) to
examine lymph node metastases from 29 patients with stage
IIIB and IIIC melanoma. Selecting a cutoff for good prognosis
of 24 months, there were 16 patients with poor prognosis and
13 with good prognosis. The mean time to progression for the
good prognosis group was 40 months compared with 4
months for the poor prognosis group. Multivariate analysis
showed no statistically significant differences in age, gender,
American Joint Committee on Cancer (AJCC) stage, the use of
adjuvant IFN therapy, or the presence of tumor-infiltrating
lymphocytes between the two patient groups. From the list of
2,140 significantly differentially expressed genes, two out-
come-related tests were developed, a 21-gene element
prognosticator and a 5-gene quantitative PCR prognosticator.
In an independent sample of 10 tumors, the quantitative PCR
predictor correctly classified 9 of them with respect to
outcome. Validation of the 21-gene signature was achieved
but with minimal statistical power (n¼4). We have recently
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completed a study (Mann et al., 2010) assessing outcome
prediction using stage III melanomas and revalidated this
signature (see below). Furthermore, several of the signature
genes, including CHST4, MFGE8, and KCNIP2, have been
linked to anticancer immune response.
2009: 266-gene (element) expression signature
In an examination of 38 metastatic melanomas, Bogunovic
et al. (2009), identified 266 genes/gene elements associated
with postrecurrence survival. This signature was assessed for
its predictive capacity against the 2001 version of the AJCC
tumor, node, metastasis (TNM) staging system (Balch et al.,
2001), for the presence of tumor-infiltrating lymphocytes,
T-cell CD3 positivity, and mitotic index. The mitotic index
was the most significant predictor of outcome (hazard
ratio¼ 2.13, P¼0.0008), a result that is now aptly reflected
by inclusion of mitotic rate as an important prognostic factor
in the current AJCC TNM staging system adopted in 2010
(Balch et al., 2009). The gene signature was, however, also a
significant and independent predictor of outcome (P¼0.03)
in a multivariate context alongside mitotic index (P¼0.0002)
but not TNM stage (P¼0.30). Encouragingly consistent
with the work of John et al. (2008), several of the signature
genes were immune response related (e.g., ICOS, CD3 delta,
ZAP70, TRAT1, TARP, GZMK, LCK, CD2, CXCL13, CCL19,
CCR7, and VCAM1). A cell proliferation theme emerged for
genes negatively associated with survival (e.g., PDE4D,
CDK2, GREF1, NUSAP1, and SPC24).
2009: osteopontin expression
Conway et al. (2009) conducted the first eligible study to
assess formalin-fixed, paraffin-embedded primary melanoma
tissue and identified osteopontin expression as predictive of
relapse-free survival in the training set. This predictive signal,
however, was not maintained in a validation set in a multi-
variate context when the top-performing histopathological
factors, namely, Breslow thickness, mitotic rate, and the
presence of ulceration, were taken into account. In spite of
this finding, these authors have attempted to address a
significant challenge to the field; banks of frozen primary
tissue are rare in melanoma. For routine patient clinical care,
melanoma specimens are usually fixed in formalin and
embedded in paraffin for histopathological diagnosis, for
assessment of prognostic parameters, and for determination
of surgical margin status. Improved assays have prompted a
revisit and analysis of the large biospecimen banks of
formalin-fixed, paraffin-embedded tissue. The Conway study
supports the view that high-throughput gene expression
studies are now possible using archival formalin-fixed,
paraffin-embedded tissue. We await upcoming publications
in the area to gain further insight into the extent of their
translational relevance, including for miRNA analysis (e.g., as
in Jukic et al., 2010).
2010: 30-gene (element) expression signature and subtype
discriminator
In the second most recent key study, Jo¨nsson et al. (2010)
examined 57 subcutaneous and lymph node melanoma
metastases. Using unsupervised hierarchical clustering and
the top 3,000 most variably expressed genes, the researchers
identified four tumor subgroups. On the basis of the within-
group gene content, subtypes were named as follows: (1) high
immune response, (2) proliferative, (3) pigmentation, and
(4) normal like. These groups were each observed to be
significantly associated with outcome, with patients in the
proliferative group having the shortest overall survival
relative to those in the other three groups. These researchers
also proposed an a priori-defined immune response-related
gene expression signature of 30 genes and tested its use in
predicting outcome. A key strength of the work is that authors
used independent in-house data (n¼20), as well as data from
John et al. (2008), Bogunovic et al. (2009), Haqq et al. (2005),
and Winnepenninckx et al. (2006), and some publicly
available cell line data to test their classifiers. Overall, the
results of that validation varied with the prediction rules
holding up in some data sets but not in others. In contrast to
prior related studies, these researchers also used comple-
mentary approaches to further characterize molecular traits
of their identified subtypes (including comparative genomic
hybridization, reverse transcriptase-PCR, immunohisto-
chemistry, examination of promoter methylation status,
multiplex ligation-dependent probe amplification, and muta-
tion screening). It is noteworthy that (1) the proliferative and
pigmentation groups were observed to be more geneti-
cally heterogeneous than the other groups when tested in
this integrated way; (2) MITF was highly expressed in the
pigmentation group; (3) methylation of p16INK4a promoter
was associated with the proliferative subtype; (4) six of the
eight tumors with CDKN2A homozygous deletions were from
the proliferative group; and (5) BRAF and NRAS mutations
were found in all groups but were most frequent in the
proliferative group.
2010: 60-probe (46-gene) expression signature
In the most recent study to date, we assayed fresh frozen
nodal metastases (n¼48) coupled with a comprehensive
clinical, pathological, and genetic assessment of both the
banked nodal melanoma and preceding primary tumor
(Mann et al., 2010). The cohort comprised patients selected
from the extremes of survival distribution (class A: poor prog-
nosis, survivalo1 year after surgical resection, died because
of melanoma, cf. class B good prognosis, survival 44 years
after surgical resection, with no sign of relapse). The clinical,
pathological, and molecular parameters (including results of
somatic mutation profiling) were analyzed using multiple
imputation and logistic regression for determinants of out-
come. The final model included the following independent
predictors of good outcome: disease stage oIII at initial
presentation; the presence of a nodular component in the
primary tumor; small cell size or lower pigmentation in the
nodal metastases; absence of BRAF or NRAS mutation; and a
46-gene (60-probe) expression signature. This gene signature
was validated using two independent later-stage melanoma
data sets (John et al., 2008; Bogunovic et al., 2009). Again
consistent with prior related studies, bioinformatics analysis
demonstrated strong overrepresentation of immune-related
278 Journal of Investigative Dermatology (2012), Volume 132
S-J Schramm et al.
Gene Expression Profiling in Melanomas
genes in the prognostic gene set. High-dimensional multi-
variate analysis showed that combining both clinicohisto-
pathological and GEMA data was more effective when
compared with reliance on either factor on its own leave-
one-out cross-validation error rate¼0.23 for the signature,
together with traditional factors cf. 0.25 and 0.27, respec-
tively, for those elements alone).
COMPARATIVE ANALYSES OF PROGNOSTIC
SIGNATURES
Direct comparison of eligible prognostic signatures
We performed bioinformatics analysis of each of the
aforementioned prognostic signatures in order to identify
similar genes between them and examine whether such
intersections may potentially illuminate pathways and
processes of interest in the broader context of disease drivers
and/or correlates. First, the published signature lists from
each eligible study were manually extracted. We applied the
‘‘Compare experiments’’ algorithm (default settings) in
MetaCore (from GeneGo) that performs mapping between
objects of each gene list and defines common, similar, and/or
unique subsets between them (not accounting for the
possibility that intersections may occur by chance) accom-
panied by gene ontology enrichment analysis. Altogether, we
observed 10 pairwise intersections among our eligible data
sets (Table 2). Among notable individual genes are those
appearing in more than one data set intersection, including
PGHD, preferentially normally expressed in the brain and a
catalyst for conversion of prostaglandin H2 to neuromodu-
lator prostaglandin D2, as well as several cluster of
differentiation (CD) molecules. Functional enrichment ana-
lysis of the union of all genes present at any intersection
between two data sets (n¼ 46, excluding those genes from
the 30-gene signature of John et al., 2008) highlighted the
immune response as a significant (Po0.05) top-ranking
biological process, contributed to by molecules such as
CD2, CD3, CD79, HLA-DQB1, ICOS, IRF8, Ikaros, LTB, and
VCAM1 (Supplementary Tables S1–3 online). G-protein
signaling-related molecules, including several from the NRAS
regulation pathway (MHC class II, CD3, LCK, and CALDAG-
GEFI), also feature when the data are analyzed in that way
(Supplementary Table S1 online). This finding is not surpris-
ing given that NRAS and downstream BRAF mutations are
present in B60% of melanomas (Lee et al., 2010). Never-
theless, the fact that the NRAS pathway signal has emerged
across different assay platforms, batches, and statistical
methods is evidence of the potential of GEMAs (singularly
and when combined with studies as we have performed here)
to produce biologically relevant output.
Cross-validation of signatures between data sets
In the second of our study comparisons, we assessed the
predictive power of each of the eligible signature gene lists in
each of the other eligible gene expression data sets (Supple-
mentary Methods online) (Table 3).
Overall, the signature with the lowest average error rate
across all validation expression data was that proposed by
Mann et al. (2010; 0.28). The John study signature also
performed well using other expression data sets (error rates
B0.2–o0.27), except the Winnepenninckx expression data.
This observation may be a reflection of stage difference; the
Winnepenninckx study involved primary melanomas,
whereas the other studies examined more advanced-stage
tumors. The Bogunovic study signature also validated
with encouragingly low error rates using the John and
Jo¨nsson expression data sets (0.17 and 0.20, respectively)
but lost its good prognostic capacity using the Mann and
Winnepenninckx expression data (0.54 and 0.48, respec-
tively). A close inspection of the cohorts presents a possible
explanation for this observation; the Bogunovic sample
included stage IV melanoma tissue, as did the Jo¨nsson study.
John et al. (2008) examined stage IIIB or higher-stage tumors,
whereas both the Mann and Winnepenninckx data sets were
derived from (slightly) earlier-stage samples (Mann: stage IIIA,
B, and C; Winnepenninckx: primary tumor/stages I and II). If
GEMAs have discriminated between cohorts on the basis of
these arguably subtle differences, then we can be, once
again, encouraged by their potential prognostic sensitivity.
However, we cannot rule out other plausible explanations for
the observed differences, including the effects of immu-
notherapy treatment of at least some patients in the
Bogunovic, John, and Jo¨nsson study cohorts, as well as
platform differences and/or varying definitions of the end
point being assessed (Table 1). Nevertheless, it is encouraging
that the later-stage signatures appear to consistently validate
with lower error rates using the later-stage expression data
relative to the Winnepenninckx primary tumor stage expres-
sion data set (although, again, the possibility that this effect
may be due to platform or other differences between studies
cannot be ruled out without further testing).
It is noteworthy that the Jo¨nsson et al. (2010) a priori-
defined, immune-related gene list performed most poorly on
average (0.45) relative to the other signatures we examined.
This occurrence appears to be in spite of a strong immune
response-related signal emanating from the combined data
sets, as confirmed in our bioinformatics analysis above. In
contrast, the Mann signature performed generally well and is
per se a highly immunological gene set. This anomaly may
reflect the improved sensitivity for prognostic gene set
detection by algorithm-based methods compared with the
more biased hand-picking approach.
DISCUSSION AND COMMENTARY
In the most recent review of melanoma GEMA prognostic
signatures, Timar et al. (2010) found little in common between
them, and they highlighted problems around sample hetero-
geneity, tissue and survival data availability, lack of indepen-
dent validation, and platform and statistical differences as the
limiting factors. In the present review, we show that work in
the field has progressed considerably in the past 18 months.
First, rigorous new studies have been published, thereby
increasing the number of data sets available for examination
and comparison. Second, we have been able to select studies
for inclusion in our review based on their fulfillment of a
simple set of minimum criteria, developed to identify studies
in the area having the greatest translational relevance.
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We observed, perhaps unexpectedly, similarities between
our carefully selected data sets despite their different platforms
and statistical methods. Most of the signatures we examined
contained an immune response theme as an overrepre-
sented process. Considering the general body of immuno-
histochemistry-based examination of melanoma proteins in a
prognostic setting (Gould Rothberg et al., 2009b), molecules
involved in altered immunocompetence have not been as
Table 2. Genes in common, pairwise (identified using MetaCore from GeneGo), between selected proposed
prognostic signatures in human melanoma
Winnepenninckx
et al. (2006)
254-object
signature
(n=207)
John et al.
(2008)
21-object
signature
(n=16)
John et al.
(2008)
5-gene qPCR
signature
(n=5)
Bogunovic
et al. (2009)
266-object
signature
(n=340)
Conway
et al. (2009)
Osteopontin
(n=1)
Jo¨nsson
et al.
(2010) 30-gene
immune
signature
(n=29)
Jo¨nsson et al.
(2010) 377-
gene molecular
subtype
discriminator
(n=349)
Winnepenninckx et al. (2006)
254-object signature (n=207)
John et al. (2008)
21-object signature (n=16)
MRPS5
John et al. (2008)
5-gene qPCR signature (n=5)
None NA
Bogunovic et al. (2009)
266-object signature (n=340)
ATAD2
Anillin
Exo1
LTB
MCM4
PGHD
TXNIP
None None
Conway et al. (2009)
Osteopontin (n=1)
None None None None
Jo¨nsson et al. (2010)
30-gene immune
signature (n=29)
None None None CD79A
LCK
SKAP55
None
Jo¨nsson et al. (2010)
377-gene molecular
subtype discriminator (n=349)
C12orf24
CLIC3
HAI-2
HLA-DQB1
ICAT
MHC class II
MHC class II
(b-chain)
PGHD
PROM2
ITPA None AADAT
ARHGAP30
CALDAG-GEFI
CDK2
DLX1
FLJ11193
G-alpha(s)-
specific,
prostanoid
GCPRs
Granzyme K
HLA-DPB1
ICOS
Ikaros
LCK
MATP
MHC class II
PGE2R2
PGHD
VNN2
None CD19
CD3
CD3 epsilon
LAX1
LCK
Mann et al. (2010)
60-probe (46-gene) signature (n=53)
None None None ADAMDEC1
CD2
CD3 zeta
CD3 delta
CD79
FAT10
GBP2
IRF8
Pleckstrin
VCAM1
None CD79 complex GBP4
Gimap4
PM17
TSPAN10
Abbreviations: NA, not applicable; qPCR, quantitative PCR.
Bracketed n-values indicate the number of genes from that particular signature that were positively identified by the MetaCore program. Genes in each box
are common between the signatures at that particular intersection. Genes in bold type are common to more than two signatures.
See text for inclusion criteria.
280 Journal of Investigative Dermatology (2012), Volume 132
S-J Schramm et al.
Gene Expression Profiling in Melanomas
actively studied (Schramm and Mann, 2011) as proteins from
other Hanahan–Weinberg (Hanahan and Weinberg, 2000)
cancer capability functional groups (e.g., tissue invasion and
metastasis or self sufficiency in growth signals). This finding
underscores the importance of a detailed, ongoing examina-
tion of the tumor microenvironment for biological correlates
with prognosis, as well as potential therapy targets, as has
been argued by others (Polak et al., 2009; Bedognetti et al.,
2010; Gajewski et al., 2010). It also reiterates the rational
platform for identification of immune response-based pre-
dictive/prognostic signatures as demonstrated by Jo¨nsson
et al. (2010) with their a priori-defined gene list, although this
particular hand-picked signature did not perform as well in
formal statistical validation as the other, less-biased gene lists.
Is it possible, however, to make a distinction between the
immune response per se (e.g., CD3 and other markers of
infiltrating cells, which could parallel and extend the analysis
of tumor-infiltrating lymphocytes, known to be prognostic in
both primary and metastatic melanomas; Payette et al., 2009)
and genes likely derived from the tumor cells themselves?
At least one such attempt has been made by Gould Rothberg
et al. (2009b) who, in their review of immunohistochemistry-
based prognostic biomarkers in melanoma, supplemented the
Hanahan–Weinberg cancer capability classification system
(Hanahan and Weinberg, 2000) with two additional mela-
noma-specific categories: ‘‘altered immunocompetence’’ and
‘‘melanocyte differentiation.’’ Molecules of prognostic inter-
est were then assigned to each of those groups (annexin,
MAGE3, and STAT1 to the former and tyrosinase, MART1,
and gp100 to the latter) based on extensive literature review
of their function.
Some of the signatures we reviewed predicted outcomes
in other, equally eligible, expression data sets with notably
low rates of misclassification. We propose that this cross-
validation illustrates the biological relevance of those parti-
cular gene lists in predicting outcome for selected subsets
of melanoma patients. Our finding is also consistent with
observations made by Weigelt et al. (2010) who, in a review
of the contribution of gene expression profiling to breast
cancer classification, reported that distinct prognostic signa-
tures for specific subgroups of breast cancer may be neces-
sary to accurately define their outcome. One such subset
could involve patients with a ‘‘proliferation’’ signature.
Weigelt et al. (2010) and other groups have observed that
breast cancer patients with the highest expression of
‘‘proliferation cluster’’ genes appear to derive most benefit
from chemotherapy. An outcome-related proliferation sub-
type comprising 100 genes/gene elements was proposed in
the Jo¨nsson study and we keenly await the results of further
examination in that area. We also look forward to further
investigation of outcome or potential therapy-related signa-
tures within the subset of BRAF-mutated melanomas, as the
distinction of these tumors as a separate molecular subgroup
becomes clearer.
A prevailing question around GEMAs in clinical practice is
whether they can outperform current clinicopathological
markers of outcome. For example, in the Winnepenninckx
study, the prognostic capacity of the gene expression data
was marginally inferior to tumor thickness and to the
presence of ulceration. In contrast, Mann et al. (2010). have
more recently presented an outcome prediction model that is
optimized when both clinicopathological factors and gene
expression data are used in combination (error rate¼0.23)
rather than alone (error rates¼0.27 and 0.25, respectively).
It has been argued that the primary purpose of a new marker
is to augment currently available knowledge (Dalton
and Kattan, 2010). Therefore, novel gene signatures should
continue to be assessed in a multivariable setting alongside
existing factors to evaluate any additive prognostic contribu-
tion of the tests combined. Efforts to begin building databases
that present gene expression data alongside corresponding
patient clinical data are in early stages; e.g., the integrated
clinical omics database (iCOD; Shimokawa et al., 2010). As
is the case for breast cancers, the value of signatures in
clinical decision making remains to be elucidated using
much larger data sets and rigorous clinical trial experimental
designs (discussed in more detail elsewhere; Pepe et al.,
2008).
One of the most pressing questions moving forward is
whether expression-based predictive/prognostic signatures
will continue to add value in clinical practice in a new era
of high-throughput genomic analyses. We agree with others
Table 3. Leave-one-out cross-validation (LOOCV) error rates for misclassification of patients into outcome-related
classes in our cross-validation of gene signatures between independent data sets
Expression data set-
Signature object list k
Bogunovic et al.
(2009)
John et al.
(2008)
Jo¨nsson et al.
(2010)
Mann et al.
(2010)
Winnepenninckx et al.
(2006)
Bogunovic et al. (2009) (n=340) 0.18 0.17 0.20 0.54 0.48
John et al. (2008) (n=16) 0.24 0.13 0.20 0.27 0.48
Jo¨nsson et al. (2010) (n=29; a priori-defined
immune signature)
0.39 0.38 0.17 0.46 0.57
Jo¨nsson et al. (2010) (n=349; molecular
subtype distinguisher)
0.42 0.08 0.17 0.38 0.74
Mann et al. (2010) (n=46) 0.36 0.13 0.30 0.35 0.35
Winnepenninckx et al. (2006) (n=207) 0.39 0.50 0.20 0.44 0.70
Bracketed n-values indicate the number of objects (e.g., genes, probes, and gene elements) assessed in each particular signature.
See Supplementary Methods online for details.
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(e.g., Tinker et al., 2006; Madabhushi et al., 2011) that the
most clinically valid and useful prognostic models will
probably continue to be derived from a combination of
techniques as a function of their costs and effectiveness. For
example, the demonstrated relevance of protein signatures by
immunohistochemistry profiling (such as in Kreizenbeck
et al., 2008; Piras et al., 2008; Gould Rothberg et al.,
2009a) and the promise of computer-assisted image analysis
(Alexe et al., 2009) all suggest that no single technique will
supplant all of the others. Many of the lessons learned
through the process of integrating useful gene expression
signatures with traditional prognostic factors are also likely to
be applicable to subsequent technologies.
Among the exciting developments for better understanding
melanoma is work being undertaken in the burgeoning
field of cancer systems biology (Hawkins et al., 2010).
Questions such as whether we can exploit our observations
of local and global melanoma gene or protein network
properties to benefit patients are pertinent (Faratian et al.,
2009). For example, using breast cancer gene expression
microarray data, Taylor et al. (2009) have proposed a method
that reveals that altered modularity of the human intera-
ctome may be useful as a prognostic indicator. In melanoma
research, the output of transcriptomic, proteomic, and
miRNA signatures is beginning to surge (Glud et al., 2009;
Han et al., 2010; Jukic et al., 2010; Philippidou et al., 2010).
Coupled with ongoing developments in gene/protein network
construction algorithms (Djebbari and Quackenbush, 2008;
Han, 2008; Kreeger and Lauffenburg, 2010), we are increas-
ingly well placed to better understand the complex interplay
of separate biological components via the network analysis
approach.
In their commentary on breast cancer GEMA, Weigelt
et al. (2010) report that, ‘‘In hindsight, the pitfalls of the
approaches chosen to define signatures predicting response,
both methodological and conceptual, have become clear to
many.’’ In the present review, we show that the benefit of this
hindsight has not been ignored by the melanoma research
community. Rather, we have reaffirmed the ongoing rele-
vance of carefully designed GEMAs to improving disease
management in the era of personalized medicine, particularly
for advanced-stage disease.
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